TAC1 and Parkinson disease: Indeed, the discovery of fiscalins A-C [28] as substance P inhibitors was also previously described as a promising novel neuroprotective therapy on early stages of PD, in an in vivo intrastriatal 6-hydroxydopamine model [29], anticipating this scaffold with potential neuroprotective properties that could be relevant for the treatment of ND, namely PD.